Hemophagocytic Lymphohistiocytosis Completed Phase 2 Trials for Alemtuzumab (DB00087)

Also known as: Hemophagocytic Lymphohistiocytosis (HLH) / Haemophagocytic Lymphohistiocytosis / Hemophagocytic Lymphohistiocytoses / Hemophagocytic Lymphohisticytosis / Hemophagocytic lymphohistiocytosis (disorder) / Lymphohistiocytosis, Hemophagocytic / Primary hemophagocytic lymphohistiocytosis / Primary haemophagocytic lymphohistiocytosis / Familial hemophagocytic lymphohistiocytosis (disorder) / Familial Hemophagocytic Lymphocytosis / Familial haemophagocytic lymphohistiocytosis / Familial hemophagocytic lymphohistiocytosis

IndicationStatusPhase
DBCOND0029166 (Hemophagocytic Lymphohistiocytosis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00368355
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell GraftsTreatment
NCT00176865
Stem Cell Transplant for Immunologic or Histiocytic DisordersTreatment